Work

Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.10535

Authors: Michael C. Heinrich, Margaret von Mehren, George D. Demetri, Jonathan A. Fletcher, Jichao G Sun, David Kerstein, Maureen G Conlan, Suzanne George

Institutions: Oregon Health & Science University, Portland VA Medical Center, OHSU Knight Cancer Institute, Fox Chase Cancer Center, Temple University Health System, Dana-Farber Brigham Cancer Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, ARIAD Pharmaceuticals (United States)

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2473386911

Cites:

Cited by: 20

Related to: 10